Ray Tabibiazar, SalioGen CEO

Gene ther­a­py 3.0 ef­forts net Sali­o­Gen a nine-fig­ure Se­ries B, but much re­mains un­der wraps

Rough­ly 10 months ago, a fledg­ling biotech emerged from stealth with a mod­est Se­ries A and a big promise look­ing to de­vel­op gene ther­a­py 3.0. The promise inched clos­er to re­al­i­ty Wednes­day as in­vestors have now hopped on board thanks to a new, nine-fig­ure round.

Sali­o­Gen Ther­a­peu­tics closed its $115 mil­lion Se­ries B, the com­pa­ny an­nounced Wednes­day morn­ing, aim­ing to push for­ward its “gene cod­ing” plat­form and grow­ing pre­clin­i­cal pipeline. The biotech, which fo­cus­es on ac­ti­vat­ing dor­mant mam­malian en­zymes to ed­it genes in vi­vo, se­cured the new raise af­ter flesh­ing out some of the tech­nolo­gies’ ap­pli­ca­tions, CEO Ray Tabib­i­azar told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.